Literature DB >> 10529902

Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications.

W Fox1, G A Ellard, D A Mitchison.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10529902

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


× No keyword cloud information.
  188 in total

Review 1.  Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective.

Authors:  Stephen H Gillespie
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis.

Authors:  A P Davies; O J Billington; T D McHugh; D A Mitchison; S H Gillespie
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

3.  A20 and ABIN-3 possibly promote regression of trehalose 6,6'-dimycolate (TDM)-induced granuloma by interacting with an NF-kappa B signaling protein, TAK-1.

Authors:  Yusuke Sakai; Kazuyuki Uchida; Hiroyuki Nakayama
Journal:  Inflamm Res       Date:  2011-12-16       Impact factor: 4.575

4.  Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.

Authors:  Jotam G Pasipanodya; Shashikant Srivastava; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2012-03-30       Impact factor: 9.079

Review 5.  New antituberculous drugs in development.

Authors:  Umesh G Lalloo; Anish Ambaram
Journal:  Curr HIV/AIDS Rep       Date:  2010-08       Impact factor: 5.071

6.  Recent advances in tuberculosis: New drugs and treatment regimens.

Authors:  Derek J Sloan; Geraint R Davies; Saye H Khoo
Journal:  Curr Respir Med Rev       Date:  2013-06-01

7.  N-methylation of a bactericidal compound as a resistance mechanism in Mycobacterium tuberculosis.

Authors:  Thulasi Warrier; Kanishk Kapilashrami; Argyrides Argyrou; Thomas R Ioerger; David Little; Kenan C Murphy; Madhumitha Nandakumar; Suna Park; Ben Gold; Jianjie Mi; Tuo Zhang; Eugenia Meiler; Mike Rees; Selin Somersan-Karakaya; Esther Porras-De Francisco; Maria Martinez-Hoyos; Kristin Burns-Huang; Julia Roberts; Yan Ling; Kyu Y Rhee; Alfonso Mendoza-Losana; Minkui Luo; Carl F Nathan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-18       Impact factor: 11.205

Review 8.  Medical management of drug-sensitive active thoracic tuberculosis: the work-up, radiographic findings and treatment.

Authors:  Jared Eddy; Taimur Khan; Frank Schembri
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

9.  Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment.

Authors:  Geraint R Davies; Richard Brindle; Saye H Khoo; Leon J Aarons
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

10.  Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.

Authors:  Weerawat Manosuthi; Chonlaphat Sukasem; Aroon Lueangniyomkul; Wiroj Mankatitham; Supeda Thongyen; Samruay Nilkamhang; Sukanya Manosuthi; Somnuek Sungkanuparph
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.